PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29599366
OWN - NLM
STAT- MEDLINE
DCOM- 20180412
LR  - 20180412
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 4
DP  - 2018 Apr
TI  - Performance Status and Number of Metastatic Extra-cerebral Sites Predict Survival
      After Radiotherapy of Brain Metastases from Thyroid Cancer.
PG  - 2391-2394
AB  - BACKGROUND/AIM: Patients with brain metastases from thyroid cancer are extremely 
      rare. This study evaluated clinical factors for survival following whole-brain
      radiotherapy (WBRT) alone. PATIENTS AND METHODS: In six patients, the following
      factors were analyzed for survival: Regimen of WBRT (5x4 Gy vs. 10x3 Gy), gender,
      age (</=55 vs. >/=56 years), Karnofsky performance score (KPS) (60% vs. 70-80%), 
      number of brain lesions (2-3 vs. >/=4) and number of extra-cranial metastatic
      sites (one vs. more than one). RESULTS: KPS 70-80% (p=0.036) and involvement of
      only one extra-cranial site (p=0.018) were associated with better survival on
      univariate analysis. On Cox regression analysis, KPS (p=0.14) and number of
      extra-cranial sites (p=0.14) showed trends for association with survival. In
      patients with KPS 70-80% and only one extra-cranial site, 6-month survival was
      100%, no patient with KPS 60% and more than one extra-cranial site survived to 6 
      months. CONCLUSION: KPS and number of involved extra-cranial metastatic sites
      were associated with survival and may be helpful for individualizing therapy in
      patients with brain metastases from thyroid cancer.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Dziggel, Liesa
AU  - Dziggel L
AD  - Department of Radiation Oncology and Hematology, University of Lubeck, Lubeck,
      Germany.
FAU - Gebauer, Niklas
AU  - Gebauer N
AD  - Department of Medical Oncology, University of Lubeck, Lubeck, Germany.
FAU - Bartscht, Tobias
AU  - Bartscht T
AD  - Department of Medical Oncology, University of Lubeck, Lubeck, Germany.
FAU - Schild, Steven E
AU  - Schild SE
AD  - Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A.
FAU - Rades, Dirk
AU  - Rades D
AD  - Department of Radiation Oncology and Hematology, University of Lubeck, Lubeck,
      Germany [email protected]
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Brain Neoplasms/*diagnosis/mortality/*radiotherapy/*secondary
MH  - *Cranial Irradiation
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Thyroid Neoplasms/*diagnosis/mortality/*pathology/*radiotherapy
OTO - NOTNLM
OT  - *Thyroid cancer
OT  - *metastatic lesions to the brain
OT  - *predictive factors
OT  - *survival
OT  - *whole-brain radiotherapy alone
EDAT- 2018/03/31 06:00
MHDA- 2018/04/13 06:00
CRDT- 2018/03/31 06:00
PHST- 2018/01/15 00:00 [received]
PHST- 2018/02/09 00:00 [revised]
PHST- 2018/02/13 00:00 [accepted]
PHST- 2018/03/31 06:00 [entrez]
PHST- 2018/03/31 06:00 [pubmed]
PHST- 2018/04/13 06:00 [medline]
AID - 38/4/2391 [pii]
AID - 10.21873/anticanres.12488 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Apr;38(4):2391-2394. doi: 10.21873/anticanres.12488.